Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

A Novel Application of Injectable PRF for Superior Sulcus Hollowing

Arslan N., Bahar A., Bilgic AA., Kakil ŞB.

Retrospective Study with a reported sample of 24 on Skin Aging, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
J Cosmet Dermatol (2026)
Reported sample size
24
Source database
Europe PMC
PMID
41560426
PMCID
PMC12820442
DOI
10.1111/jocd.70666
Citations
1

Abstract (original English)

Background Superior sulcus hollowing is a frequent esthetic concern, commonly managed with synthetic fillers or fat grafts; however, these approaches carry potential risks and costs. Injectable platelet-rich fibrin (i-PRF), an autologous regenerative biomaterial, has shown promise in dermatologic and dental applications, but its use for periocular volume restoration remains unexplored. Aims To evaluate the efficacy, safety, and patient satisfaction of i-PRF injections for the correction of superior sulcus hollowing. Patients/methods This single-center retrospective study included 24 eyes of 12 patients treated with i-PRF between 2021 and 2024. Sulcus depth was measured at baseline and at 3 and 6 months posttreatment. Subjective satisfaction was assessed using a binary scale. i-PRF was prepared using a low-speed centrifugation protocol and injected suborbicularis in three sessions spaced 1 week apart. Results A significant reduction in superior sulcus depth was observed from baseline to 3 months (13.3 ± 2.8 mm to 9.2 ± 3.7 mm; p = 0.002), followed by mild regression at 6 months (10.5 ± 3.3 mm). Patient satisfaction was high, with 18 out of 24 eyes (75%) reporting favorable outcomes at 3 months. No adverse effects were recorded. Conclusions This first clinical report of i-PRF for upper eyelid hollowing suggests that it may serve as a safe, autologous, and minimally invasive alter

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
EyelidsHumansTreatment OutcomeCosmetic TechniquesRetrospective StudiesSkin AgingAdultAgedMiddle AgedPatient Satisfaction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research